DUR Oversight

Drug Utilization Review Board

The DUR Board consists of four physicians and four pharmacists who each serve a two-year term. The board members have three responsibilities:

  • an advisory role providing medical and pharmaceutical expertise to the Ohio DUR program;
  • the development of standards and criteria for retrospective drug utilization review; and
  • the development of educational outreach programs for physicians and pharmacists.

The Board meets quarterly to approve criteria, guidelines, research activities and promote educational outreach activities.

DUR Board Members

  • David C. Brookover, R.Ph.
  • Michael Dietz, D.O.
  • Michael K. Farrell, M.D.
  • Robert B. Kubasak, R.Ph.
  • A. Mehran Mostafavifar, M.D., MBA
  • Lenard G. Presutti, D.O.
  • Stacey Rexrode-Brewer, Pharm. D
  • Donald L. Sullivan, Ph.D., R.Ph.

Drug Utilization Review Committee

The Committee meets monthly to review consumer claims profiles as part of a focused review.

The Committee helps determine specific review criteria for each intervention. Selected consumer profiles are reviewed by the DUR committee and chosen for intervention. Intervention letters may then be sent to the physician and/or pharmacy. In addition, DUR committee members may select cases they feel should be referred for a more detailed review of either the recipient or provider. Those profiles are then referred to the Coordinated Service Program (CSP) or to the Surveillance and Utilization Review Section.

DUR Committee Members

  • David C. Brookover, R.Ph.
  • Benjamin Michaels, Pharm.D.
  • Kayla Petkus, Pharm.D.
  • Jeffrey Michael Rabe, Pharm.D.
  • Paulette Rhoden, Pharm.D.
  • William R. Casee Seibert, Pharm.D.
  • Jill Wellmeier, R.Ph.